Lp-PLA2 Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus
Titin Andri Wihastuti,1 Fitria Nugraha Aini,2,3 Cholid Tri Tjahjono,4 Yuni Hendrati Sulfia,3 Zuhrotus Sholichah,3 Teuku Heriansyah5 1Department of Basic Science in Nursing, Faculty of Medicine, University of Brawijaya, Malang, East Java, Indonesia; 2Faculty of Medicine, University of Islam Malang, M...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-11-01
|
Series: | Vascular Health and Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/lp-pla2-selective-inhibitor-darapladib-effect-in-lowering-the-expressi-peer-reviewed-article-VHRM |
id |
doaj-11fee68e123e44f483e97fc585370537 |
---|---|
record_format |
Article |
spelling |
doaj-11fee68e123e44f483e97fc5853705372020-11-25T01:36:07ZengDove Medical PressVascular Health and Risk Management1178-20482019-11-01Volume 1550350849436Lp-PLA2 Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes MellitusWihastuti TAAini FNTjahjono CTSulfia YHSholichah ZHeriansyah TTitin Andri Wihastuti,1 Fitria Nugraha Aini,2,3 Cholid Tri Tjahjono,4 Yuni Hendrati Sulfia,3 Zuhrotus Sholichah,3 Teuku Heriansyah5 1Department of Basic Science in Nursing, Faculty of Medicine, University of Brawijaya, Malang, East Java, Indonesia; 2Faculty of Medicine, University of Islam Malang, Malang, East Java, Indonesia; 3Master Programme of Biomedicine, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia; 4Department of Cardiology and Vascular Medicine, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia; 5Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Syiah Kuala, Banda Aceh, Aceh, IndonesiaCorrespondence: Teuku HeriansyahDepartment of Cardiology and Vascular Medicine, Faculty of Medicine, Syiah Kuala University, St. Teuku Nyak Arief Darussalam, Banda Aceh, Aceh 23111, IndonesiaTel +62 81-1661-8282Email teuku_hery@unsyiah.ac.idPurpose: The aim of this study is to prove that type 2 diabetes mellitus can induce increasing inflammation marker in renal and that the provision of darapladib as Lp-LA2 Inhibitor agents can inhibit inflammation that were measured from the expression of IL-1B and IL-6- type cytokine in renal. This study also discusses the correlation between IL-1B and IL-6- type cytokine expression in renal.Methods: Thirty Sprague-Dawley (SD) rats were divided into three main groups; those are negative control group (NC), Type 2 Diabetes Mellitus group (T2DM) given high fat diet (HFD) with streptozotocin intraperitoneal injection (35mg/kg BW) and diabetes mellitus + darapladib group (DM + DP). Each group was treated within two serial treatment time: 8 weeks and 16 weeks. Expressions of IL-1B and IL-6- type cytokine in renal were the markers that we measured by immunofluorosense method.Results: The administration of darapladib can significantly decrease the expression of IL-1B- type cytokine (p ANOVA = 0.029, p < 0.005) measured in rats’ renal both at weeks 8 and 16 in the T2DM group. The Expression of IL-6- type cytokine also showed a significant difference after treated with darapladib both at weeks 8 and 16 in T2DM group with p-value of ANOVA = 0.033, p < 0.005. The Pearson correlation showed a strong correlation (linear regression value was r2 = 0.743).Conclusion: Our results show that atherosclerosis caused by inflammation in renal T2DM SD rats could be inhibited by the administration of darapladib.Keywords: IL-1B- type cytokine, IL-6- type cytokine, kidney organ, diabetes mellitus type 2, darapladibhttps://www.dovepress.com/lp-pla2-selective-inhibitor-darapladib-effect-in-lowering-the-expressi-peer-reviewed-article-VHRMil-1b- type cytokineil-6- type cytokinekidney organdiabetes melitus type 2darapladib |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wihastuti TA Aini FN Tjahjono CT Sulfia YH Sholichah Z Heriansyah T |
spellingShingle |
Wihastuti TA Aini FN Tjahjono CT Sulfia YH Sholichah Z Heriansyah T Lp-PLA2 Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus Vascular Health and Risk Management il-1b- type cytokine il-6- type cytokine kidney organ diabetes melitus type 2 darapladib |
author_facet |
Wihastuti TA Aini FN Tjahjono CT Sulfia YH Sholichah Z Heriansyah T |
author_sort |
Wihastuti TA |
title |
Lp-PLA2 Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus |
title_short |
Lp-PLA2 Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus |
title_full |
Lp-PLA2 Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus |
title_fullStr |
Lp-PLA2 Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus |
title_full_unstemmed |
Lp-PLA2 Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus |
title_sort |
lp-pla2 selective inhibitor (darapladib) effect in lowering the expression level of il-1b and il-6 in the renal at type 2 diabetes mellitus |
publisher |
Dove Medical Press |
series |
Vascular Health and Risk Management |
issn |
1178-2048 |
publishDate |
2019-11-01 |
description |
Titin Andri Wihastuti,1 Fitria Nugraha Aini,2,3 Cholid Tri Tjahjono,4 Yuni Hendrati Sulfia,3 Zuhrotus Sholichah,3 Teuku Heriansyah5 1Department of Basic Science in Nursing, Faculty of Medicine, University of Brawijaya, Malang, East Java, Indonesia; 2Faculty of Medicine, University of Islam Malang, Malang, East Java, Indonesia; 3Master Programme of Biomedicine, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia; 4Department of Cardiology and Vascular Medicine, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia; 5Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Syiah Kuala, Banda Aceh, Aceh, IndonesiaCorrespondence: Teuku HeriansyahDepartment of Cardiology and Vascular Medicine, Faculty of Medicine, Syiah Kuala University, St. Teuku Nyak Arief Darussalam, Banda Aceh, Aceh 23111, IndonesiaTel +62 81-1661-8282Email teuku_hery@unsyiah.ac.idPurpose: The aim of this study is to prove that type 2 diabetes mellitus can induce increasing inflammation marker in renal and that the provision of darapladib as Lp-LA2 Inhibitor agents can inhibit inflammation that were measured from the expression of IL-1B and IL-6- type cytokine in renal. This study also discusses the correlation between IL-1B and IL-6- type cytokine expression in renal.Methods: Thirty Sprague-Dawley (SD) rats were divided into three main groups; those are negative control group (NC), Type 2 Diabetes Mellitus group (T2DM) given high fat diet (HFD) with streptozotocin intraperitoneal injection (35mg/kg BW) and diabetes mellitus + darapladib group (DM + DP). Each group was treated within two serial treatment time: 8 weeks and 16 weeks. Expressions of IL-1B and IL-6- type cytokine in renal were the markers that we measured by immunofluorosense method.Results: The administration of darapladib can significantly decrease the expression of IL-1B- type cytokine (p ANOVA = 0.029, p < 0.005) measured in rats’ renal both at weeks 8 and 16 in the T2DM group. The Expression of IL-6- type cytokine also showed a significant difference after treated with darapladib both at weeks 8 and 16 in T2DM group with p-value of ANOVA = 0.033, p < 0.005. The Pearson correlation showed a strong correlation (linear regression value was r2 = 0.743).Conclusion: Our results show that atherosclerosis caused by inflammation in renal T2DM SD rats could be inhibited by the administration of darapladib.Keywords: IL-1B- type cytokine, IL-6- type cytokine, kidney organ, diabetes mellitus type 2, darapladib |
topic |
il-1b- type cytokine il-6- type cytokine kidney organ diabetes melitus type 2 darapladib |
url |
https://www.dovepress.com/lp-pla2-selective-inhibitor-darapladib-effect-in-lowering-the-expressi-peer-reviewed-article-VHRM |
work_keys_str_mv |
AT wihastutita lppla2selectiveinhibitordarapladibeffectinloweringtheexpressionlevelofil1bandil6intherenalattype2diabetesmellitus AT ainifn lppla2selectiveinhibitordarapladibeffectinloweringtheexpressionlevelofil1bandil6intherenalattype2diabetesmellitus AT tjahjonoct lppla2selectiveinhibitordarapladibeffectinloweringtheexpressionlevelofil1bandil6intherenalattype2diabetesmellitus AT sulfiayh lppla2selectiveinhibitordarapladibeffectinloweringtheexpressionlevelofil1bandil6intherenalattype2diabetesmellitus AT sholichahz lppla2selectiveinhibitordarapladibeffectinloweringtheexpressionlevelofil1bandil6intherenalattype2diabetesmellitus AT heriansyaht lppla2selectiveinhibitordarapladibeffectinloweringtheexpressionlevelofil1bandil6intherenalattype2diabetesmellitus |
_version_ |
1725064039259701248 |